ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites. Metabolomics (which is the study of small molecules such as glucose or cholesterol) is essential for developing the right therapeutics for the right patients. However, because identifying a large set of metabolites for each patient is costly and slow, metabolomic data has been under-utilized – until now!
ReviveMed technology, which was developed at MIT and published in Nature Methods, uniquely overcomes the difficulty of using a large set of metabolomic data, and transform these data into actionable insight. Currently, we selected a few strategic clients from leading pharma/biotech companies to provide them with drug de-risking, biomarker discovery and therapeutic solutions. In the meanwhile, we are developing in-house therapeutic solutions for neurodegenerative and liver diseases.